Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats

Life Sciences

Volumn 72, Issue 24, 2003, Pages 2695-2705

  Okumura, Michiaki ^a   Imanishi, Masahito ^a   Okamura, Mikio ^b   Hosoi, Masayuki ^a   Okada, Noriyuki ^a   Konishi, Yoshio ^a   Morikawa, Takashi ^a   Miura, Katsuyuki ^b   Nakatani, Tatsuya ^b   Fujii, Satoru ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

2,3 dinor thromboxane B2; OKY 046; Otsuka Long Evans Tokushima Fatty rats; Platelets; Thromboxane B2

Indexed keywords

OZAGREL; THROMBOXANE A2; 6 OXOPROSTAGLANDIN F1 ALPHA; ENZYME INHIBITOR; METHACRYLIC ACID DERIVATIVE; PROSTAGLANDIN; THROMBOXANE SYNTHASE;

ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULOSCLEROSIS; HISTOLOGY; KIDNEY DISEASE; MALE; MEDICAL EXAMINATION; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RAT; REDUCTION; THROMBOCYTE AGGREGATION; URINARY EXCRETION; AGING; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; DRUG ANTAGONISM; GLUCOSE BLOOD LEVEL; MESANGIUM; METABOLISM; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOLOGY; PHYSIOLOGY; THROMBOSIS; URINE;

6-KETOPROSTAGLANDIN F1 ALPHA; AGING; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ENZYME INHIBITORS; GLOMERULAR MESANGIUM; MALE; METHACRYLATES; PROSTAGLANDINS; PROTEINURIA; RATS; RATS, INBRED OLETF; THROMBOSIS; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 0037414399     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00180-2     Document Type: Article

References (27)

1. 2 in cyclosporin A nephrotoxicity. Kidney International. 34(2):1988;164-174.
2. Bruggeman L.A., Horigan E.A., Horikoshi S., Ray P.E., Klotman P.E. Thromboxane stimulates synthesis of extracellular matrix proteins in vitro. American Journal of Physiology. 261(3 Pt 2):1991;F488-F494.
3. Bruggeman L.A., Pellicoro J.A., Horigan E.A., Klotman P.E. Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression. Kidney International. 43(6):1993;1219-1225.
4. Catella F., Nowak J., FitzGerald G.A. Measurement of renal and non-renal eicosanoid synthesis. American Journal of Medicine. 81(Suppl. 2B):1986;23-29.
5. Craven P.A., Melhem M.F., DeRubertis F.R. Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney International. 42(4):1992;937-946.
6. DeRubertis F.R., Craven P.A. Contribution of platelet thromboxane production to enhanced urinary excretion and glomerular production of thromboxane and to the pathogenesis of albuminuria in the streptozotocin-diabetic rat. Metabolism. 41(1):1992;90-96.
7. DeRubertis F.R., Craven P.A. Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. American Journal of Kidney Diseases. 22(5):1993;727-735.
8. FitzGerald G.A., Oates J.A., Hawiger J., Maas R.L., Roberts L.J.D., Lawson J.A., Brash A.R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. Journal of Clinical Investigation. 71(3):1983;676-688.
9. FitzGerald G.A., Pedersen A.K., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 67(6):1983;1174-1177.
10. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Science USA. 72(8):1975;2994-2998.
11. Hora K., Oguchi H., Furukawa T., Hora K., Tokunaga S. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy. Nephron. 56(3):1990;297-305.
12. Inagawa T., Imaki K., Masuda H., Morikawa Y., Hirata F., Tsuboshima M. Simplified immunoassays of prostaglandin E main metabolite in human urine. Advances in Prostaglandin, Thromboxane, and Leukotriene Research. 11:1983;191-196.
13. Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 41(11):1992;1422-1428.
14. Okumura M., Imanishi M., Yamashita T., Yamamura Y., Kim S., Iwao H., Tanaka S., Fujii S. Renal production of thromboxane and prostaglandins in a rat model of type 2 diabetes. Life Sciences. 66(5):2000;371-377.
15. Olson J.L., Heptinstall R.H. Nonimmunologic mechanisms of glomerular injury. Laboratory Investigation. 59(5):1988;564-578.
16. 2 in health and disease. Advances in Prostaglandin, Thromboxane, and Leukotriene Research. 11:1983;493-498.
17. Patrono C., Davi G. Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes/Metabolism Reviews. 9(3):1993;177-188.
18. Quilley J., McGiff J.C. Influence of insulin on urinary eicosanoid excretion in rats with experimental diabetes mellitus. Journal of Pharmacology and Experimental Therapeutics. 238(2):1986;606-611.
19. Raij L., Azar S., Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney International. 26(2):1984;137-143.
20. Reilly I.A.G., Doran J.B., Smith B., FitzGerald G.A. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation. 73(6):1986;1300-1309.
21. Reilly I.A.G., Roy L., FitzGerald G.A. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. British Medical Journal. 292(6527):1986;1037-1039.
22. Remuzzi G., FitzGerald G.A., Patrono C. Thromboxane synthesis and action within the kidney. Kidney International. 41(6):1992;1483-1493.
23. 2 in man. Identification of twenty urinary metabolites. Journal of Biological Chemistry. 256(16):1981;8384-8393.
24. Schlondorff D., Ardaillou R. Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney International. 29(1):1986;108-119.
25. Sowers J.R., Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 26(6 Pt 1):1995;869-879.
26. Winocour P.D. Platelets, vascular disease, and diabetes mellitus. Canadian Journal of Physiology and Pharmacology. 72(3):1994;295-303.
27. 2 synthesis caused by cicletanine in patients with essential hypertension. American Journal of Hypertension. 8(9):1995;944-948.